Quantum-Si to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

GUILFORD, Conn.--()--Quantum-Si Incorporated (Nasdaq: QSI), a life sciences tools company commercializing a unique protein sequencing platform, today announced that it will participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum. John Stark, Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will participate in a virtual fireside chat on Thursday, November 18, 2021 at 2:30 p.m. ET.

A webcast of the event will be available on the Investors section of Quantum-Si’s website under Events & Presentations. A replay will be available on the Company’s website after the event.

About Quantum-Si

Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Contacts

Investor Contacts
Juan Avendano
VP of Investor Relations
(413) 537-8735
javendano@quantum-si.com

Mike Cavanaugh
ICR Westwicke
(617) 877-9641
ir@quantum-si.com

Media Contact
Cammy Duong
ICR Westwicke
(203) 682-8380
QSI-PR@westwicke.com

Release Summary

Quantum-Si to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Contacts

Investor Contacts
Juan Avendano
VP of Investor Relations
(413) 537-8735
javendano@quantum-si.com

Mike Cavanaugh
ICR Westwicke
(617) 877-9641
ir@quantum-si.com

Media Contact
Cammy Duong
ICR Westwicke
(203) 682-8380
QSI-PR@westwicke.com